Solid lipid nanoparticles: Influence of composition, fabrication methods and problems, in vitro drug release and intranasal administration provide to access olfactory bulb pathway for SLNs
1 Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
2 Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
3 Department of pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
4 Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
5 Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Dist.-Dhule, Shirpur, Maharashtra, India 425405.
Review Article
GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 126-142.
Article DOI: 10.30574/gscbps.2021.14.2.0049
Publication history:
Received on 16 January 2021; revised on 17 February 2021; accepted on 19 February 2021
Abstract:
Background: Solid lipid nanoparticles (SLN) have drawn increasing interest in recent years. These nanoparticles are formed from stable or solid lipid mixtures and then stabilized by emulsifiers. As nanoparticles, colloidal particles running in size somewhere in the 10 to 1000 nm range are known. SLN provides fascinating properties, such as minimal scale, massive surface area, high medication piling, correspondence of stages at the interface, and is interested in their ability to enhance drug execution.
Main text: This paper provides a description of the choice of ingredients, the effect of lipids and their structure on the formulation, and the various methods of processing SLN. We explain the characteristics of SLN stability and the possibilities of SLN stabilization by lyophilization in this article. The relation between drug absorption and the complexity of SLN dispersions, which involves the existence of other colloidal structures and the physical state of the lipid, is uncommonly considered. We define the possible problems of SLN preparation and performance on the basis of characterization. First, the nasal route was known to accomplish the avoidance of first-pass hepatic metabolism in order to maximize absolute bioavailability, and secondly, the immediate nose-to-brain pathway to enhance the delivery of brain medicines. SLNs have been designated to increase drug permeability through the blood-brain barrier as a drug delivery device (BBB).
Conclusion: To sum up, this article gives insight SLNs a colloidal drug carrier places together the compensations of polymeric nanoparticles, SLNs have numerous benefits such as easy incorporation of lipid and lipophilic as well as hydrophilic drugs, suitable physical stability, and available at low cost and easy to manufacture. The nasal route was accepted to exploit first its prevention of the hepatic first-pass metabolism to increase the absolute bioavailability, and second, the direct nose-to-brain pathway to enhance the brain drug delivery. SLNs were chosen as a drug delivery system to improve drug permeability across the blood-brain barrier (BBB) and consequently its brain delivery.
Keywords:
Solid Lipid Nanoparticles; Lipid Nanocarriers: High-Pressure Homogenization (HPH); Lyophilization; Intranasal Delivery; Blood Brain Barrier (BBB)
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
